Pfizer's 2025 Outlook: Is This the Breakthrough Investors Have Been Waiting For?

GuruFocus.com12-18 01:28

Pfizer (NYSE:PFE) just dropped some solid news for investors: 2025 revenue projections are right where Wall Street expected, between $61 billion and $64 billion, with adjusted earnings per share (EPS)...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2492996148?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/rdKihtm6fVJGe5OInRyDkQ--~B/aD01MDA7dz01MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/808431929aeb6d847eefb98fc2f80936","is_english":true,"pubTime":"2024-12-18 01:28","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2492996148","market":"us","top_or_hot":-1,"title":"Pfizer's 2025 Outlook: Is This the Breakthrough Investors Have Been Waiting For?","media":"GuruFocus.com","content":"<div>\n<p>Pfizer (NYSE:PFE) just dropped some solid news for investors: 2025 revenue projections are right where Wall Street expected, between $61 billion and $64 billion, with adjusted earnings per share (EPS)...</p>\n\n<a href=\"https://finance.yahoo.com/news/pfizers-2025-outlook-breakthrough-investors-172819569.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer's 2025 Outlook: Is This the Breakthrough Investors Have Been Waiting For?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer's 2025 Outlook: Is This the Breakthrough Investors Have Been Waiting For?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-18 01:28 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/pfizers-2025-outlook-breakthrough-investors-172819569.html><strong>GuruFocus.com</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pfizer (NYSE:PFE) just dropped some solid news for investors: 2025 revenue projections are right where Wall Street expected, between $61 billion and $64 billion, with adjusted earnings per share (EPS)...</p>\n\n<a href=\"https://finance.yahoo.com/news/pfizers-2025-outlook-breakthrough-investors-172819569.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SG9999001176.USD","symbol_name":"United Global Healthcare Acc USD","start_time":0,"source_url":"https://finance.yahoo.com/news/pfizers-2025-outlook-breakthrough-investors-172819569.html","article_id":"2492996148","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/rdKihtm6fVJGe5OInRyDkQ--~B/aD01MDA7dz01MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/808431929aeb6d847eefb98fc2f80936"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2492996148","pubTimestamp":1734456499,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Pfizer  just dropped some solid news for investors: 2025 revenue projections are right where Wall Street expected, between $61 billion and $64 billion, with adjusted earnings per share  estimated at $2.80 to $3.00. The company's cost-cutting efforts are making a real impact, with $4 billion in savings expected by the end of 2024 and another $500 million in 2025. This is a welcome boost after a rough year, where shares have dropped almost 12%, but Pfizer's ability to bounce back from the COVID-era slump is encouraging.GuruFocus has detected 7 Warning Signs with PFE.Despite facing some serious heat from activist investor Starboard Valuewho's been vocal about overspending on acquisitions like Seagen and falling short on internal R&DPfizer's outlook is staying steady. The company's latest projections signal that it's getting back on track with revenue growth, largely thanks to its renewed focus on cost discipline and margin improvement. However, Pfizer's pipeline still has a lot of pressur","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"SG9999001176.USD":"United Global Healthcare Acc USD","LU1894683348.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) INC","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","SG9999003800.SGD":"Nikko AM Global Dividend Equity Acc SGD-H","LU0306807586.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" (USD) INC QF","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","BK4581":"高盛持仓","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","BK4592":"伊斯兰概念","BK4599":"减肥药","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","ISBC":"投资者银行","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","BK4585":"ETF&股票定投概念","BK4534":"瑞士信贷持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","BK4211":"区域性银行","SG9999011175.SGD":"Nikko AM Global Dividend Equity Dis SGD-H","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","PFE":"辉瑞","LU0321505439.SGD":"Schroder ISF Global Dividend Maximiser A Acc SGD","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","SG9999002232.USD":"Allianz Global High Payout USD","LU0234572021.USD":"高盛美国核心股票组合Acc","LU0985481810.HKD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (HKD) INC M","LU0058720904.USD":"联博国际健康护理基金A","SG9999002224.SGD":"Allianz Global High Payout SGD","LU0306806265.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" ACC","LU1894683264.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) ACC","BK4550":"红杉资本持仓","BK4588":"碎股","BK4568":"美国抗疫概念","LU0225771236.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (USD) INC MF","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","LU1883839398.USD":"AMUNDI FUNDS INCOME OPPORTUNITIES \"A2\" (USD) ACC","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","LU0122379950.USD":"贝莱德世界健康科学A2","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","LU0225284248.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" ACC"},"translate_title":"辉瑞2025年展望：这是投资者一直在等待的突破吗？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ISBC":1,"PFE":1},"content_text":"Pfizer (NYSE:PFE) just dropped some solid news for investors: 2025 revenue projections are right where Wall Street expected, between $61 billion and $64 billion, with adjusted earnings per share (EPS) estimated at $2.80 to $3.00. The company's cost-cutting efforts are making a real impact, with $4 billion in savings expected by the end of 2024 and another $500 million in 2025. This is a welcome boost after a rough year, where shares have dropped almost 12%, but Pfizer's ability to bounce back from the COVID-era slump is encouraging.\n\nWarning! GuruFocus has detected 7 Warning Signs with PFE.\n\nDespite facing some serious heat from activist investor Starboard Valuewho's been vocal about overspending on acquisitions like Seagen and falling short on internal R&DPfizer's outlook is staying steady. The company's latest projections signal that it's getting back on track with revenue growth, largely thanks to its renewed focus on cost discipline and margin improvement. However, Pfizer's pipeline still has a lot of pressure riding on it, especially after a few missteps, like the disappointing obesity drug trials and some lukewarm vaccine launches.\nBut, here's the thing: Pfizer is staying on course. While the company faces challenges, particularly with new market pressures like changes to Medicare's prescription plan under the Inflation Reduction Act, its forecast for 2025 still seems achievable. Analysts are cautiously optimistic, with many believing that Pfizer's ongoing restructuring efforts could spark the next phase of growth. It's not all smooth sailing yet, but Pfizer's strategy to push through these bumps could give it the fuel it needs for a comeback in the years ahead.This article first appeared on \nGuruFocus.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2492996148"}